Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia

Fig. 4The alternative text for this image may have been generated using AI.

STAR-T-cell pharmacokinetics and changes in LILRB4-positive cells following infusion. a qPCR and flow cytometry were used to determine the copy numbers of the LILRB4 STAR and LILRB4+ cells in PBMCs from each patient. b qPCR and flow cytometry were used to determine the copy numbers of LILRB4-expressing STAR and LILRB4+ cells, respectively, in the BM of each patient. c Changes in the number of LILRB4-positive and LILRB4-negative cells before and after the infusion of STAR-T cells into the patient’s PB for 14 days. d Comparison of the peak numbers of LILRB4-expressing STAR-T cells between responsive and nonresponsive patients. The results are presented as the mean ± SEM, and p values were determined by paired t tests. p = 0.1000

Back to article page